Explore the words cloud of the EU-rhythmy project. It provides you a very rough idea of what is the project "EU-rhythmy" about.
The following table provides information about the project.
UNIVERSITA DEGLI STUDI DI PAVIA
|Coordinator Country||Italy [IT]|
|Total cost||2˙314˙029 €|
|EC max contribution||2˙314˙029 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2015-11-01 to 2020-10-31|
Take a look of project's partnership.
|1||UNIVERSITA DEGLI STUDI DI PAVIA||IT (PAVIA)||coordinator||1˙334˙029.00|
|2||CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.)||ES (MADRID)||participant||600˙000.00|
|3||AVANTEA srl||IT (Cremona)||participant||380˙000.00|
Sudden cardiac death (SCD) is a leading cause of death in western countries: coronary artery disease is the major cause of SCD in older subjects while inherited arrhythmogenic diseases are the leading cause of SCD in younger individuals. After 25 years dedicated to research of the molecular bases of heritable arrhythmias, the PI of this proposal now intends to pioneer gene therapy for prevention of SCD: a virtually unexplored field. The development of molecular therapies for rhythm disturbances is a high risk effort however, if successful, it will be highly rewarding. The PI has envisioned an ambitious and comprehensive project to target two severe inherited arrhythmogenic diseases: dominant catecholaminergic polymorphic ventricular tachycardia (CPVT) and Long QT syndrome type 8 (LQT8). The availability of a clinically relevant model is critical to ensure clinical translation of results: the team will exploit an existing CPVT model and will engineer a knock-in pig to model LQT8. The PI and her team will investigate innovative strategies of gene-delivery, gene-silencing and gene-editing to the heart comparing efficacy of different constructs and promoters. The team will also carefully engineer novel gene-therapy approaches to avoid the development of regional inhomogeneity in protein expression that may facilitate proarrhythmic events. Such a comprehensive approach will provide a most valuable core of knowledge on the comparative efficacy of a broad range of molecular strategies on the electrical milieu of the heart. It is expected that these results will not only benefit CPVT and LQT8 but rather they will foster development of gene therapy for other inherited and acquired arrhythmias.
|year||authors and title||journal||last update|
Rossana Bongianino, Marco Denegri, Andrea Mazzanti, Francesco Lodola, Alessandra Vollero, Simona Boncompagni, Silvia Fasciano, Giulia Rizzo, Damiano Mangione, Serena Barbaro, Alessia Di Fonso, Carlo Napolitano, Alberto Auricchio, Feliciano Protasi, Silvia G. Priori
Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene ( RYR2 )Novelty and Significance
published pages: 525-536, ISSN: 0009-7330, DOI: 10.1161/CIRCRESAHA.117.310882
|Circulation Research 121/5||2020-04-23|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EU-RHYTHMY" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EU-RHYTHMY" are provided by the European Opendata Portal: CORDIS opendata.
Righting Victim Participation in Transitional JusticeRead More
Elucidating the development of sexually-dimorphic circuits: from molecular mechanisms to synapses and behaviorRead More
Economic Fluctuations, Productivity Growth and Stabilization Policies: A Keynesian Growth PerspectiveRead More